KR20110044883A - 신규한 조성물 및 방법 - Google Patents

신규한 조성물 및 방법 Download PDF

Info

Publication number
KR20110044883A
KR20110044883A KR1020117004640A KR20117004640A KR20110044883A KR 20110044883 A KR20110044883 A KR 20110044883A KR 1020117004640 A KR1020117004640 A KR 1020117004640A KR 20117004640 A KR20117004640 A KR 20117004640A KR 20110044883 A KR20110044883 A KR 20110044883A
Authority
KR
South Korea
Prior art keywords
polypeptide
protein sequence
rv3616c protein
tuberculosis
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117004640A
Other languages
English (en)
Korean (ko)
Inventor
제임스 브라운
파스칼 메텐스
데니스 머피
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이., 글락소 그룹 리미티드 filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Publication of KR20110044883A publication Critical patent/KR20110044883A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
KR1020117004640A 2008-07-25 2009-07-24 신규한 조성물 및 방법 Ceased KR20110044883A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8372008P 2008-07-25 2008-07-25
US61/083,720 2008-07-25
PCT/EP2009/059580 WO2010010177A1 (en) 2008-07-25 2009-07-24 Novel compositions and methods

Publications (1)

Publication Number Publication Date
KR20110044883A true KR20110044883A (ko) 2011-05-02

Family

ID=41217660

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117004640A Ceased KR20110044883A (ko) 2008-07-25 2009-07-24 신규한 조성물 및 방법

Country Status (24)

Country Link
US (2) US20110117119A1 (https=)
EP (1) EP2315773B1 (https=)
JP (1) JP5873332B2 (https=)
KR (1) KR20110044883A (https=)
CN (1) CN102164952B (https=)
AU (1) AU2009273130B2 (https=)
BR (1) BRPI0916703A2 (https=)
CA (1) CA2731499C (https=)
CO (1) CO6341637A2 (https=)
CY (1) CY1118200T1 (https=)
DK (1) DK2315773T3 (https=)
EA (1) EA024826B1 (https=)
ES (1) ES2602430T3 (https=)
HR (1) HRP20161458T1 (https=)
HU (1) HUE031044T2 (https=)
IL (1) IL210559A0 (https=)
LT (1) LT2315773T (https=)
MX (1) MX2011000983A (https=)
PL (1) PL2315773T3 (https=)
PT (1) PT2315773T (https=)
SG (1) SG192456A1 (https=)
SI (1) SI2315773T1 (https=)
UA (1) UA107330C2 (https=)
WO (1) WO2010010177A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940406B2 (en) 2008-08-13 2015-01-27 Novelis Inc. Automobile body part

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1144447T3 (da) * 1998-11-04 2010-02-08 Isis Innovation Dianostisk tuberkulosetest
AU2009273132B2 (en) 2008-07-25 2015-09-03 Glaxo Group Limited The tuberculosis Rv2386c protein, compositions and uses thereof
CA2731549C (en) 2008-07-25 2018-07-17 Glaxo Group Limited Compositions and methods for treating tuberculosis
MX2011011186A (es) 2009-04-24 2012-02-13 Una vacuna antituberculosis tb para evitar la reactivacion.
BR112012018669A2 (pt) 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
BR112016006284B1 (pt) 2013-09-27 2022-07-26 Codexis, Inc Método implementado por computador, produto de programa de computador, e, sistema de computador
RU2016116253A (ru) 2013-09-27 2017-11-01 Кодексис, Инк. Автоматизированный скрининг вариантов фермента
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN106546737A (zh) * 2016-10-24 2017-03-29 广州迪澳医疗科技有限公司 一种体外检测活动性结核的方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
WO2020210630A1 (en) 2019-04-12 2020-10-15 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
CN115073612B (zh) * 2022-06-22 2024-09-27 宁夏大学 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途
GB202318595D0 (en) * 2023-12-05 2024-01-17 Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency Diagnostic proteins and reagents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
PL202844B1 (pl) * 1998-04-07 2009-07-31 Corixa Corp Immunogeniczny polipeptyd, polinukleotyd, polipeptyd, kompozycja farmaceutyczna, wektor ekspresji, kompozycja szczepionki, polipeptyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis, polinukleotyd do stosowania w leczeniu lub zapobieganiu infekcjom Mycobacterium tuberculosis i sposób wytwarzania polipeptydu
US7083796B2 (en) * 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
NZ526807A (en) * 2001-01-08 2005-03-24 Isis Innovation Assay to determine efficacy of treatment for mycobacterial infection
US20040121322A9 (en) * 2001-02-22 2004-06-24 Cole Stewart T. Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
US20030236393A1 (en) * 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
EP2226332A1 (en) * 2004-06-17 2010-09-08 Beckman Coulter, Inc. Mycobacterium tuberculosis epitopes and methods of use thereof
DK2457926T3 (da) 2005-04-29 2015-01-05 Glaxosmithkline Biolog Sa Ny fremgangsmåde til forebyggelse eller behandling af M. tuberkulose-infektion
BRPI0612833A2 (pt) * 2005-06-23 2010-11-30 Statens Seruminstitut composição imunogênica, vacina, composição farmacêutica, polipeptìdeo de fusão e uso das três primeiras
WO2008007942A1 (en) * 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
US9297803B2 (en) * 2006-11-01 2016-03-29 Immport Therapeutics, Inc. Compositions and methods for immunodominant antigens
MX2011011186A (es) * 2009-04-24 2012-02-13 Una vacuna antituberculosis tb para evitar la reactivacion.
BR112012018669A2 (pt) 2010-01-27 2017-09-05 Glaxosmithkline Biologicals Sa Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8940406B2 (en) 2008-08-13 2015-01-27 Novelis Inc. Automobile body part

Also Published As

Publication number Publication date
UA107330C2 (uk) 2014-12-25
AU2009273130A1 (en) 2010-01-28
SI2315773T1 (sl) 2016-12-30
CO6341637A2 (es) 2011-11-21
PL2315773T3 (pl) 2017-07-31
EP2315773A1 (en) 2011-05-04
CY1118200T1 (el) 2017-06-28
US20140178423A1 (en) 2014-06-26
HUE031044T2 (en) 2017-06-28
EP2315773B1 (en) 2016-08-24
JP2011528895A (ja) 2011-12-01
LT2315773T (lt) 2016-11-10
DK2315773T3 (en) 2016-12-12
CN102164952A (zh) 2011-08-24
US9795663B2 (en) 2017-10-24
BRPI0916703A2 (pt) 2019-12-24
CA2731499A1 (en) 2010-01-28
EA201100072A1 (ru) 2011-10-31
ES2602430T3 (es) 2017-02-21
SG192456A1 (en) 2013-08-30
US20110117119A1 (en) 2011-05-19
WO2010010177A1 (en) 2010-01-28
AU2009273130B2 (en) 2014-10-16
CN102164952B (zh) 2016-05-25
HRP20161458T1 (hr) 2016-12-16
JP5873332B2 (ja) 2016-03-01
IL210559A0 (en) 2011-03-31
CA2731499C (en) 2017-01-10
EA024826B1 (ru) 2016-10-31
PT2315773T (pt) 2016-11-23
MX2011000983A (es) 2011-03-02

Similar Documents

Publication Publication Date Title
JP6104326B2 (ja) 結核Ｒｖ２３８６ｃタンパク質、組成物およびその使用
JP5873332B2 (ja) 新規化合物および方法
JP5824360B2 (ja) 新規化合物および方法
WO2010010178A1 (en) The tuberculosis rv2707c protein, compositions and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110225

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140718

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151126

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160527

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20151126

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I